このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Alligator Bioscience 過去の業績

過去基準チェック /06

Alligator Bioscienceの収益は年間平均-7%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間11.8% 36.6%割合で増加しています。

主要情報

-7.0%

収益成長率

29.4%

EPS成長率

Biotechs 業界の成長	0.7%
収益成長率	36.6%
株主資本利益率	n/a
ネット・マージン	-440.5%
次回の業績アップデート	11 Jul 2024

Recent updates

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Aug 18

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Apr 11

Estimating The Intrinsic Value Of Alligator Bioscience AB (publ) (STO:ATORX)

Feb 17

収支内訳

Alligator Bioscience の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:ATORX 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費
31 Mar 24	56	-249	82
31 Dec 23	59	-249	79
30 Sep 23	68	-232	76
30 Jun 23	53	-231	75
31 Mar 23	40	-213	72
31 Dec 22	36	-193	69
30 Sep 22	21	-177	65
30 Jun 22	20	-163	63
31 Mar 22	18	-152	59
31 Dec 21	13	-142	57
30 Sep 21	8	-139	54
30 Jun 21	5	-133	51
31 Mar 21	6	-133	53
31 Dec 20	6	-143	56
30 Sep 20	5	-169	59
30 Jun 20	9	-194	62
31 Mar 20	4	-209	62
31 Dec 19	4	-210	61
30 Sep 19	30	-181	60
30 Jun 19	26	-164	58
31 Mar 19	26	-152	55
31 Dec 18	27	-150	52
30 Sep 18	53	-107	54
30 Jun 18	54	-93	51
31 Mar 18	55	-86	48
31 Dec 17	57	-64	44
30 Sep 17	12	-96	40
30 Jun 17	15	-77	37
31 Mar 17	18	-91	35
31 Dec 16	59	-48	33
30 Sep 16	55	-68	31
31 Dec 15	292	207	32
31 Dec 14	1	-77	31

質の高い収益: ATORXは現在利益が出ていません。

利益率の向上: ATORXは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ATORXは利益が出ておらず、過去 5 年間で損失は年間7%の割合で増加しています。

成長の加速: ATORXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ATORXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 3% ) と比較することは困難です。

株主資本利益率

高いROE: ATORXの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Alligator Bioscience 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

Third quarter 2023 earnings released

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Recent updates

Alligator Bioscience Announces Results from the Ongoing Optimize-1 Trial

Alligator Bioscience AB (publ) to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024

Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting

Alligator Bioscience Announces Initiation of an Investigator-Initiated Phase 1 Clinical Study of Mitazalimab in Local Advanced Pancreatic Cancer

Consensus EPS estimates upgraded to kr0.46 loss, revenue downgraded

Alligator Bioscience AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024

High number of new directors

Alligator Bioscience AB (Publ) Announces Graham Dixon and Veronica Wallin Not Proposed for Re-Election on Board

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Alligator Bioscience Announces Cost Reduction Program to Align Key Priorities and Maximize Long-Term Value Creation

Alligator Bioscience Announces Positive Top-Line Results from the Optimize-1 Phase 2 Study of the Company's Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

New minor risk - Share price stability

Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Appoints Bertil Brinck as Chairman of the Nomination Committee

New minor risk - Profitability

Third quarter 2023 earnings released

Alligator Bioscience Grants New Composition of Matter Patent in Europe for Mitazalimab

Alligator Bioscience AB (publ) Announces Resignation of Malin Carlsson as Chief Operating Officer At the End of October

Price target decreased by 19% to kr1.90

Second quarter 2023 earnings released: kr0.19 loss per share (vs kr0.21 loss in 2Q 2022)

Alligator Bioscience AB (Publ) Announces Executive Changes

Alligator Bioscience AB (publ) Announces Phase II Results Indicate Durability of Response for Alligator's CD40 Agonist

Alligator Bioscience Announces Positive Second Interim Results from the Ongoing Optimize-1 Phase 2 Study of the Lead Asset Mitazalimab in 1st Line Metastatic Pancreatic Cancer

Consensus revenue estimates increase by 11%

Price target decreased by 36% to kr2.33

Alligator Bioscience to Present Latest Clinical Data from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer At Asco Annual Meeting 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Alligator Bioscience AB (Publ) Announces Management Changes

Alligator Bioscience Promotes Laura Von Schantz to Chief Technology Officer

Full year 2022 earnings released: kr0.88 loss per share (vs kr0.64 loss in FY 2021)

Alligator Bioscience Announces Positive Interim Results from Mitazalimab Optimize-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate

Alligator Bioscience Announces Publication Highlighting Phase 1 Mitazalimab Data in Solid Tumors in Peer-Reviewed Journal

We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate

High number of new directors

Third quarter 2022 earnings released: kr0.23 loss per share (vs kr0.43 loss in 3Q 2021)

Alligator Bioscience Announces Positive Safety Data from 900 mg Dose Cohort in ATOR-1017 Phase 1 Dose Escalation Study in Patients with Advanced Solid Malignancies

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Alligator Bioscience Presents Additional Data from Mitazalimab OPTIMIZE-1 Phase 1B/2 Trial at AACR Special Conference on Pancreatic Cancer 2022

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: kr0.21 (vs kr0.41 loss in 2Q 2021)

Alligator Bioscience AB (publ), Annual General Meeting, May 03, 2023

Alligator Bioscience AB (publ) Appoints Sumeet Ambarkhane as Its Chief Medical Officer

Vice Chairman of the Board recently bought kr152k worth of stock

Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022

Alligator Bioscience Expands Its Board of Directors with the Appointment of Staffan Encrantz and Denise Goode

Consensus forecasts updated

Chief Executive Officer recently bought kr51k worth of stock

Price target decreased to kr2.80

Less than half of directors are independent

Alligator Bioscience AB (publ) Announces Completion of 600 Mg Dose Cohort for ATOR-1017, Dose-Escalation and Enrollment for 900 Mg Dose Cohort Commences

Consensus revenue estimates increase by 255%

Alligator Bioscience AB (publ) to Report Q3, 2022 Results on Oct 20, 2022

Alligator Bioscience Appoints Sumeet Ambarkhane as Chief Medical Officer

Alligator Bioscience Announces Optimize-1 Trial Update

Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?

Third quarter 2021 earnings released: kr0.43 loss per share (vs kr0.43 loss in 3Q 2020)

Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation

Consensus revenue estimates increase to kr5.00m

Alligator Bioscience AB (Publ) Initiates A Phase II Trial with Mitazalimab, and Drug Candidate Ator-1017 Is Soon to Follow

Alligator Bioscience AB and Scandion Oncology A/S Present Promising Preclinical Data

Independent Director Kenth Petersson has left the company

Independent Director Kirsten Drejer has left the company

Independent Director Jonas Sjögren has left the company

Independent Director Ulrika Danielsson has left the company

Independent Chairman Peter Benson has left the company

Alligator Bioscience Presents Positive Phase I Data At ASCO for Its 4-1BB Agonist Drug Candidate ATOR-1017

過去基準チェック /06